Thorough QT study with recommended and supratherapeutic doses of tolterodine.
B
B
Olshansky
D B
DB
Serra
D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D003408:Cresols / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004348:Drug Labeling; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D018579:Patient Selection; D010665:Phenylpropanolamine / Q000008:administration & dosage / Q000009:adverse effects*; D012107:Research Design; D018570:Risk Assessment; D012307:Risk Factors; D000068737:Tolterodine Tartrate; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate